Malignant Skin Melanoma T0
2 clinical trials · Condition
◉ Watch Malignant Skin Melanoma T0
| Record | Firm | Date |
|---|---|---|
| DERM US and EU Validation Study (NCT05126173) | Skin Analytics Limited | 2022-03-15 |
| Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas. (NCT01168050) | Assistance Publique - Hôpitaux de Paris | 2010-07-01 |
Track Malignant Skin Melanoma T0 automatically
Every clearance here is in the API, with alerts when new ones post.